JP5416110B2 - ｉｎｖｉｖｏ細胞死を検出するためにｍｉＲＮＡを使用する方法 - Google Patents

ｉｎｖｉｖｏ細胞死を検出するためにｍｉＲＮＡを使用する方法 Download PDF

Info

Publication number
JP5416110B2
JP5416110B2 JP2010521887A JP2010521887A JP5416110B2 JP 5416110 B2 JP5416110 B2 JP 5416110B2 JP 2010521887 A JP2010521887 A JP 2010521887A JP 2010521887 A JP2010521887 A JP 2010521887A JP 5416110 B2 JP5416110 B2 JP 5416110B2
Authority
JP
Japan
Prior art keywords
mirna
urine
specific
sample
body fluid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010521887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536372A (ja
JP2010536372A5 (enExample
Inventor
ユージーン エム． シェクトマン，
ホブセフ エス． メルコニヤン，
サムイル アール． ウマンスキー，
Original Assignee
トローバジーン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40378881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5416110(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by トローバジーン インコーポレイテッド filed Critical トローバジーン インコーポレイテッド
Publication of JP2010536372A publication Critical patent/JP2010536372A/ja
Publication of JP2010536372A5 publication Critical patent/JP2010536372A5/ja
Application granted granted Critical
Publication of JP5416110B2 publication Critical patent/JP5416110B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2010521887A 2007-08-22 2008-08-22 ｉｎｖｉｖｏ細胞死を検出するためにｍｉＲＮＡを使用する方法 Expired - Fee Related JP5416110B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96587107P 2007-08-22 2007-08-22
US60/965,871 2007-08-22
PCT/US2008/009991 WO2009025852A2 (en) 2007-08-22 2008-08-22 Methods of using mirna for detection of in vivo cell death

Publications (3)

Publication Number Publication Date
JP2010536372A JP2010536372A (ja) 2010-12-02
JP2010536372A5 JP2010536372A5 (enExample) 2011-10-06
JP5416110B2 true JP5416110B2 (ja) 2014-02-12

Family

ID=40378881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010521887A Expired - Fee Related JP5416110B2 (ja) 2007-08-22 2008-08-22 ｉｎｖｉｖｏ細胞死を検出するためにｍｉＲＮＡを使用する方法

Country Status (16)

Country Link
US (4) US8486626B2 (enExample)
EP (2) EP2612926B1 (enExample)
JP (1) JP5416110B2 (enExample)
CN (2) CN101861399B (enExample)
AU (2) AU2008289447B2 (enExample)
CA (1) CA2696403C (enExample)
CY (1) CY1114111T1 (enExample)
DK (2) DK2195450T4 (enExample)
ES (2) ES2660785T3 (enExample)
HR (1) HRP20130618T1 (enExample)
HU (1) HUE019019T5 (enExample)
NO (1) NO2612926T3 (enExample)
PL (2) PL2195450T3 (enExample)
PT (2) PT2195450E (enExample)
TR (1) TR201802758T4 (enExample)
WO (1) WO2009025852A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2271931A4 (en) * 2008-04-25 2011-10-12 Merck Sharp & Dohme MICRO-RNA BIOMARKERS FOR TISSUE INJURIES
WO2010004562A2 (en) * 2008-07-09 2010-01-14 Rosetta Genomics Ltd. Methods and compositions for detecting colorectal cancer
ES2532153T3 (es) * 2008-07-18 2015-03-24 Trovagene, Inc. Métodos para la detección de secuencias de ácidos nucleicos "ultracortos" basados en PCR
EP2419536A4 (en) * 2009-04-14 2012-09-05 Merck Sharp & Dohme MICRO RNA AS A BIOMARKER FOR IMPROVING BETAZELLES IN THE PANCREAS ISLANDS
CA2767616A1 (en) 2009-07-09 2011-01-13 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
WO2011057003A2 (en) 2009-11-04 2011-05-12 Samuil Umansky Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
DK2496720T3 (da) * 2009-11-06 2020-09-28 Univ Leland Stanford Junior Ikke-invasiv diagnose af transplantatafstødning i organ-transplanterede patienter
SG185544A1 (en) * 2010-05-14 2012-12-28 Fluidigm Corp Nucleic acid isolation methods
JP6211511B2 (ja) 2011-04-18 2017-10-11 ディアミール, エルエルシーDiamir, Llc ｍｉＲＮＡに基づくユニバーサルスクリーニングテスト（ＵＳＴ）
CN102188719B (zh) * 2011-05-12 2012-12-19 南方医科大学 EB病毒miR-BART3反义寡聚核苷酸在制备治疗鼻咽癌的药物中的应用
CA2840196C (en) 2011-06-27 2022-09-20 Eisai R&D Management Co., Ltd. Microrna biomarkers indicative of alzheimer's disease
WO2013022953A2 (en) * 2011-08-08 2013-02-14 Eugenia Wang Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
CA3069089A1 (en) * 2011-09-22 2013-03-28 Lineage Biosciences, Inc. Compositions and methods for analyzing heterogeneous samples
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
EP3584327A1 (en) * 2012-01-27 2019-12-25 The Board of Trustees of the Leland Stanford Junior University Methods for profiling and quantitating cell-free rna
US20160289762A1 (en) 2012-01-27 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiliing and quantitating cell-free rna
US20140087964A1 (en) * 2012-09-24 2014-03-27 University Of Virginia Patent Foundation Compositions and methods for detecting aberrant regulation, expression, and levels of hgh
EP2733219B1 (en) 2012-11-16 2017-09-20 Siemens Aktiengesellschaft Diagnostic miRNA markers for Alzheimer
US10011873B2 (en) 2012-11-16 2018-07-03 Universitat Des Saarlandes Diagnostic miRNA markers for Parkinson disease
EP2733220B1 (en) 2012-11-16 2017-10-18 Siemens Aktiengesellschaft Novel miRNA as a diagnostic marker for Alzheimer's Disease
CN103045596A (zh) * 2012-12-20 2013-04-17 徐勇 唐氏综合征21号染色体相关miRNA、基因、筛选方法和应用
CN103045736B (zh) * 2012-12-20 2014-09-17 徐勇 唐氏综合征21号染色体miRNA差异表达图谱模型、构建方法及应用
EP2759602A1 (en) 2013-01-25 2014-07-30 Charité - Universitätsmedizin Berlin Non-invasive prenatal genetic diagnostic methods
EP2970959B1 (en) 2013-03-15 2018-05-30 Lineage Biosciences, Inc. Methods and compositions for tagging and analyzing samples
CN105917005B (zh) 2013-11-18 2020-09-11 迪阿米尔有限责任公司 使用来自体液的miRNA检测和监控帕金森病(PD)的方法
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
TWI758011B (zh) 2014-07-18 2022-03-11 香港中文大學 Ｄｎａ混合物中之組織甲基化模式分析
EP3298169B1 (en) 2015-05-18 2024-10-02 Karius, Inc. Compositions and methods for enriching populations of nucleic acids
US10428391B2 (en) 2015-07-27 2019-10-01 The Johns Hopkins University Method to use viral and host methylation markers for cervical cancer screening and triage in liquid prep, serum/plasma, and urine: PCR and sequencing based process methods
WO2017044710A1 (en) * 2015-09-11 2017-03-16 Corning Incorporated Compositions and methods for nucleic acid purification from blood samples
US10975436B2 (en) 2016-01-05 2021-04-13 Diamir, Llc Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
EP3433381B1 (en) 2016-03-21 2024-07-24 Diamir, LLC Methods of using mirnas from bodily fluids for detection and differentiation of neurodegenerative diseases
WO2018045359A1 (en) * 2016-09-02 2018-03-08 Karius, Inc. Detection and treatment of infection during pregnancy
US11001891B2 (en) 2016-11-14 2021-05-11 Berg Llc Methods for treating Parkinson's disease
IL266347B2 (en) 2016-11-30 2025-01-01 Univ Hong Kong Chinese Analysis of cell-free DNA in urine and other samples
US10907211B1 (en) 2017-02-16 2021-02-02 Quantgene Inc. Methods and compositions for detecting cancer biomarkers in bodily fluids
US10781487B2 (en) 2017-07-24 2020-09-22 Diamir, Llc miRNA-based methods for detecting and monitoring aging
SG11202003588QA (en) 2017-09-20 2020-05-28 Molecular Stethoscope Inc Methods and systems for detecting tissue conditions
GB2615975B (en) 2019-02-14 2023-11-29 Mirvie Inc Methods and systems for determining a pregnancy-related state of a subject
WO2021085505A1 (ja) * 2019-10-29 2021-05-06 国立研究開発法人 国立循環器病研究センター 脳梗塞治療支援システム
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856088A (en) 1989-07-11 1999-01-05 Gen-Probe Incorporated Detection of human immunodeficiency virus type 1
US5168039A (en) 1990-09-28 1992-12-01 The Board Of Trustees Of The University Of Arkansas Repetitive DNA sequence specific for mycobacterium tuberculosis to be used for the diagnosis of tuberculosis
US6020124A (en) 1992-04-27 2000-02-01 Trustees Of Dartmouth College Detection of soluble gene sequences in biological fluids
CA2167693C (en) 1993-07-20 2007-01-30 Ulrich Bogdahn Melanoma-inhibiting protein
AU7375794A (en) 1993-07-28 1995-02-28 Akzo Nobel N.V. Process for isolating nucleic acid from gram positive microorganisms
JP3696238B2 (ja) 1993-08-30 2005-09-14 プロメガ・コーポレイシヨン 核酸精製用組成物及び方法
US5631130A (en) 1994-05-13 1997-05-20 Abbott Laboratories Materials and methods for the detection of Mycobacterium tuberculosis
ATE261496T1 (de) 1994-06-09 2004-03-15 Innogenetics Nv Verfahren zum nachweis des antibiotikaresistenzspektrums von mykobakterium spezies
US5731150A (en) 1995-11-01 1998-03-24 Chiron Diagnostic Corporation IS6110 based molecular detection of mycobacterium tuberculosis
US6027945A (en) 1997-01-21 2000-02-22 Promega Corporation Methods of isolating biological target materials using silica magnetic particles
US6492144B1 (en) 1997-05-30 2002-12-10 Diagen Corporation Methods for detection of nucleic acid sequences in urine
US20020119478A1 (en) 1997-05-30 2002-08-29 Diagen Corporation Methods for detection of nucleic acid sequences in urine
PT2216416E (pt) 1997-05-30 2012-08-16 Trovagene Inc Métodos para detecção de sequências de ácido nucleico na urina
US5962665A (en) 1997-06-16 1999-10-05 Abbott Laboratories Nucleic acid primers and probes for detecting HIV-1 and HIV-2
US20060204989A1 (en) * 1998-09-22 2006-09-14 Kopreski Michael S Comparative analysis of extracellular RNA species
US7196183B2 (en) 2001-08-31 2007-03-27 Innogenetics N.V. Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent
US20040053264A1 (en) 2002-02-01 2004-03-18 Park Sung Sup Clinical panel assay using DNA chips
EP2471924A1 (en) * 2004-05-28 2012-07-04 Asuragen, INC. Methods and compositions involving microRNA
ITRM20050068A1 (it) 2005-02-17 2006-08-18 Istituto Naz Per Le Malattie I Metodo per la rivelazione di acidi nucleici di agenti patogeni batterici o di parassiti nelle urine.
US7914982B2 (en) 2005-02-17 2011-03-29 Trovagene, Inc. Methods for detecting pathogen specific nucleic acids in urine
ITRM20050067A1 (it) 2005-02-17 2006-08-18 Istituto Naz Per Le Malattie I Metodo per la rivelazione di acidi nucleici virali o di origine virale nelle urine.
EP1885877A2 (en) 2005-02-17 2008-02-13 Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS Compositions and methods for detecting pathogen specific nucleic acids in urine
CA2597948A1 (en) 2005-02-17 2006-08-24 Istituto Nazionale Per Le Malattie Infettive Irccs Lazzaro Spallanzani Compositions and methods for detecting viral specific nucleic acids in urine
US20060292616A1 (en) * 2005-06-23 2006-12-28 U.S. Genomics, Inc. Single molecule miRNA-based disease diagnostic methods
DE102005059315A1 (de) * 2005-12-09 2007-06-14 Qiagen Gmbh Verfahren zur Anreicherung von kurzkettigen Nukleinsäuren
US20070202511A1 (en) * 2006-02-28 2007-08-30 Sigma-Aldrich Co. Methods and compositions for the rapid isolation of small RNA molecules
ES2532153T3 (es) 2008-07-18 2015-03-24 Trovagene, Inc. Métodos para la detección de secuencias de ácidos nucleicos "ultracortos" basados en PCR

Also Published As

Publication number Publication date
US20150197805A1 (en) 2015-07-16
EP2195450B2 (en) 2016-07-20
EP2195450B1 (en) 2013-04-03
JP2010536372A (ja) 2010-12-02
PT2612926T (pt) 2018-03-02
TR201802758T4 (tr) 2018-03-21
AU2014210676B2 (en) 2017-04-06
CN105400868A (zh) 2016-03-16
CN105400868B (zh) 2021-03-26
HK1218767A1 (zh) 2017-03-10
EP2195450A2 (en) 2010-06-16
AU2008289447B2 (en) 2014-09-04
EP2612926A1 (en) 2013-07-10
CN101861399A (zh) 2010-10-13
HRP20130618T1 (en) 2013-07-31
EP2612926B1 (en) 2017-11-29
AU2008289447A1 (en) 2009-02-26
DK2612926T3 (en) 2018-03-12
DK2195450T4 (en) 2016-10-24
US8486626B2 (en) 2013-07-16
US20180135126A1 (en) 2018-05-17
US20090081640A1 (en) 2009-03-26
CA2696403C (en) 2018-01-02
HUE019019T5 (en) 2017-04-28
DK2195450T3 (da) 2013-06-24
ES2660785T3 (es) 2018-03-26
ES2415245T5 (es) 2016-12-23
PT2195450E (pt) 2013-07-10
WO2009025852A2 (en) 2009-02-26
CA2696403A1 (en) 2009-02-26
NO2612926T3 (enExample) 2018-04-28
CN101861399B (zh) 2015-11-25
AU2014210676A1 (en) 2014-08-28
ES2415245T3 (es) 2013-07-24
CY1114111T1 (el) 2016-07-27
US20200283851A1 (en) 2020-09-10
WO2009025852A3 (en) 2009-05-07
PL2612926T3 (pl) 2018-07-31
PL2195450T3 (pl) 2013-09-30

Similar Documents

Publication Publication Date Title
CA2696403C (en) Methods of using mirna for detection of in vivo cell death
JP2010536372A5 (enExample)
CN106029900B (zh) 尿生物标志物群、基因表达特征及其使用方法
EP2742155A2 (en) Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
CN112980941B (zh) 一种诊断受试者是否患阿尔茨海默病的试剂盒及其用途
CN111733227A (zh) 特发性视神经炎诊断分子标记物circRNA、试剂盒及应用
KR102545543B1 (ko) BK 바이러스 신병증의 진단을 위한 소변 엑소좀 유래 miRNA 유전자 바이오마커 및 이의 용도
KR102505618B1 (ko) 신장이식 후 항체 매개성 거부반응의 진단을 위한 소변 엑소좀 유래 miRNA 유전자 바이오마커 및 이의 용도
CN105950705B (zh) 一组microRNAs在制备阿尔兹海默氏症诊断试剂或诊断试剂盒中的应用
KR102505617B1 (ko) 신장이식 후 T 세포 매개성 거부반응의 진단을 위한 소변 엑소좀 유래 miRNA 유전자 바이오마커 및 이의 용도
HK1218767B (en) Methods of using mirna for detection of in vivo cell death
JP5988022B2 (ja) ソラフェニブの効果予測方法
CN111363808B (zh) 一种与阿尔茨海默相关的生物标志物及其应用
WO2024200806A1 (en) Gene transcripts as signatures for tead-active cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110309

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20110325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110309

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130624

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130724

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130823

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130925

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131016

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131114

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees